Brainstorm Cell Therapeutics Stock Cash Per Share
| GHDN Stock | EUR 2.69 0.00 0.00% |
Brainstorm Cell Therapeutics fundamentals help investors to digest information that contributes to Brainstorm Cell's financial success or failures. It also enables traders to predict the movement of Brainstorm Stock. The fundamental analysis module provides a way to measure Brainstorm Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brainstorm Cell stock.
Brainstorm |
Brainstorm Cell Therapeutics Company Cash Per Share Analysis
Brainstorm Cell's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Brainstorm Cell Cash Per Share | 0.29 X |
Most of Brainstorm Cell's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brainstorm Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Brainstorm Cell Therapeutics has a Cash Per Share of 0.29 times. This is 93.33% lower than that of the Healthcare sector and 93.3% lower than that of the Biotechnology industry. The cash per share for all Germany stocks is 94.21% higher than that of the company.
Brainstorm Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brainstorm Cell's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics of similar companies.Brainstorm Cell is currently under evaluation in cash per share category among its peers.
Brainstorm Fundamentals
| Return On Equity | -1.93 | |||
| Return On Asset | -0.68 | |||
| Current Valuation | 44.56 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 22.70 % | |||
| Shares Owned By Institutions | 10.41 % | |||
| Price To Book | 36.30 X | |||
| EBITDA | (24.28 M) | |||
| Net Income | (24.46 M) | |||
| Cash And Equivalents | 6.22 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 3.04 M | |||
| Debt To Equity | 934.00 % | |||
| Current Ratio | 0.97 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (26.27 M) | |||
| Earnings Per Share | (0.68) X | |||
| Target Price | 11.5 | |||
| Number Of Employees | 43 | |||
| Beta | -0.36 | |||
| Market Capitalization | 74.73 M | |||
| Total Asset | 29.28 M | |||
| Z Score | 14.4 | |||
| Net Asset | 29.28 M |
About Brainstorm Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brainstorm Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.